An Open-label, Phase 1 Study to Characterize the Effects of a Strong CYP3A4 Inducer on the Pharmacokinetics of MK-8527 in Healthy Adult Participants
Latest Information Update: 12 Aug 2025
At a glance
- Drugs Carbamazepine (Primary) ; MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 29 Jul 2025 Status changed from active, no longer recruiting to completed.
- 04 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2025 Planned End Date changed from 19 Jun 2025 to 11 Jul 2025.